Literature DB >> 15996797

Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G.

Juan Carlos Sanz-Moreno1, Aurora Limia-Sánchez, Luis García-Comas, M Mar Mosquera-Gutiérrez, Juan Emilio Echevarria-Mayo, Ana Castellanos-Nadal, Fernando de Ory-Manchón.   

Abstract

The aim of this study was to discriminate between primary and secondary vaccine failure in children with mumps using IgG avidity testing. Thirty-nine serum samples from children with mumps, confirmed by specific IgM, were studied. The patients were grouped according to their immunization status. The secondary immune response was defined by IgG with an avidity index >32%. A secondary response in infected children previously immunized was considered as a secondary vaccine failure. Vaccinated children presented higher IgG titers and IgG avidity than unvaccinated children. The proportion of secondary immune responses in unvaccinated patients was lower than that obtained in previously vaccinated infected patients. Avidity testing can be a useful tool to detect secondary vaccine failure in mumps.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996797     DOI: 10.1016/j.vaccine.2005.05.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

2.  Immune responses to mumps vaccine in adults who were vaccinated in childhood.

Authors:  Rima Hanna-Wakim; Linda L Yasukawa; Phillip Sung; Ann M Arvin; Hayley A Gans
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

3.  Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens.

Authors:  Jennifer D Boddicker; Paul A Rota; Trisha Kreman; Andrea Wangeman; Louis Lowe; Kimberly B Hummel; Robert Thompson; William J Bellini; Michael Pentella; Lucy E Desjardin
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

4.  High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.

Authors:  Karen K Yam; Erica Gipson; Marina Klein; Sharon Walmsley; David Haase; Scott Halperin; David Scheifele; Brian J Ward; Curtis Cooper
Journal:  J Clin Immunol       Date:  2014-05-14       Impact factor: 8.317

5.  Circulation of mumps virus genotypes in Spain from 1996 to 2007.

Authors:  J E Echevarría; A Castellanos; J C Sanz; C Pérez; G Palacios; M V Martínez de Aragón; I Peña Rey; M Mosquera; F de Ory; E Royuela
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948

6.  Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.

Authors:  Mohammed Ata Ur Rasheed; Carole J Hickman; Marcia McGrew; Sun Bae Sowers; Sara Mercader; Amy Hopkins; Vickie Grimes; Tianwei Yu; Jens Wrammert; Mark J Mulligan; William J Bellini; Paul A Rota; Walter A Orenstein; Rafi Ahmed; Srilatha Edupuganti
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-03       Impact factor: 12.779

7.  Outbreaks of mumps: an observational study over two decades in a single hospital in Korea.

Authors:  Ji-Ung Ryu; Eun-Kyung Kim; You-Sook Youn; Jung-Woo Rhim; Kyung-Yil Lee
Journal:  Korean J Pediatr       Date:  2014-09-30

8.  Healthcare workers' knowledge and practices regarding expanded program on immunization in Kalasin, Thailand.

Authors:  Onprasonk Widsanugorn; Onprasonk Suwattana; Md Harun-Or-Rashid; Junichi Sakamoto
Journal:  Nagoya J Med Sci       Date:  2011-08       Impact factor: 1.131

9.  Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection.

Authors:  Sara Mercader; Marcia McGrew; Sun B Sowers; Nobia J Williams; William J Bellini; Carole J Hickman
Journal:  mSphere       Date:  2018-09-12       Impact factor: 4.389

10.  Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin.

Authors:  Qingwei Luo; Tim J Vickers; James M Fleckenstein
Journal:  Clin Vaccine Immunol       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.